Company: LGN
Filing Date: 2025-11-03
Form Type: DRS
Source: 0001193125-25-262782
Chunk: 81

Company: Legence Corp.
Filing Date: 2025-11-03
Form: DRS
Chunk 81
---
 analysts;                                                                                      |

| • |     | speculation in the press or investment community; |

| • |     | the failure of research analysts to cover our Class A Common Stock; |

| • |     | sales of our Class A Common Stock by us or other stockholders, or the perception that such sales may occur; |

| • |     | changes in accounting principles, policies, guidance, interpretations or standards; |

| • |     | additions or departures of key management personnel; |

| • |     | actions by our stockholders; |

| • |     | general market conditions, including fluctuations in commodity prices; |

| • |     | domestic and international economic, legal and regulatory factors unrelated to our performance; and |

| • |     | the realization of any risks described under this “Risk Factors” section. |

48

Confidential Treatment Requested by Legence Corp.

Pursuant to 17 C.F.R. Section 200.83

The stock markets in general have experienced extreme volatility that has often been
unrelated to the operating performance of particular companies. These broad market fluctuations may adversely affect the trading price of our Class A Common Stock. Securities class action litigation has often been instituted against
companies following periods of volatility in the overall market and in the market price of a company’s securities. Such litigation, if instituted against us, could result in substantial costs, divert our management’s attention and
resources and harm our business, financial condition and results of operations.

Our Sponsor controls a significant percentage of our voting power.

The Aggregators (which are controlled by our Sponsor) beneficially own approximately 72% of our outstanding Common Stock.
Immediately following this offering, the Aggregators will beneficially own % (or %, if the underwriters exercise in full their option to purchase additional shares) of our outstanding Common
Stock. As such, our Sponsor has the power to control our business and affairs. In addition, certain of our directors are currently employed by our Sponsor. Consequently, our Sponsor will be able to influence matters that require approval by our
stockholders, including the election and removal of directors, changes to our organizational documents and approval of acquisition offers and other significant corporate transactions. This concentration of ownership will limit your ability to
influence corporate matters, and as a result, actions may be taken that you may not view as beneficial. This concentration of stock ownership may also adversely affect the trading price of our Class A Common Stock to the extent investors
perceive a disadvantage in owning stock